Remote Anxiety Management for ICS-resistant Asthma Study
This study, the Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS), explores strategies to improve medication adherence and anxiety management in asthma patients who are resistant to using inhaled corticosteroids (ICS) due to anxiety. Asthma is a chronic respiratory disease affecting millions worldwide,
| Condition(s) | Asthma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study, the Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS), explores strategies to improve medication adherence and anxiety management in asthma patients who are resistant to using inhaled corticosteroids (ICS) due to anxiety. Asthma is a chronic respiratory disease affecting millions worldwide, and ICS therapy is essential for controlling symptoms and preventing severe exacerbations. However, many patients struggle with adherence, especially those with anxiety about ICS side effects. RAMICS is a multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of personalized telephone-based interventions, including medication education, progressive muscle relaxation (PMR), motivational interviewing (MI), and lung rehabilitation guidance. T |
| Who can participate | Inclusion Criteria: 1. Age Requirement: Participants must be aged 18 to 80 years, ensuring they are adults capable of making decisions and responding effectively to interventions. 2. Diagnosed Asthma: 1. Diagnosis must meet the criteria of the Global Initiative for Asthma (GINA) or the American Academy of Asthma guidelines, with at least one confirmed diagnosis by a specialist in the past six months. 2. Asthma severity must range from mild to moderate persistent, in the chronic management phase, excluding patients in acute exacerbation phases for clearer evaluation of adherence and intervention effects. 3. ICS Treatment History: 1. Participants must have been on inhaled corticosteroid (ICS) therapy for at least six months, ensuring sufficient treatment history for adherence and effect eval |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | First Affiliated Hospital of Ningbo University |
| Locations | Harbin, China; Hefei, China; Hefei, China; Hefei, China; Jingzhou, China; Ningbo, China (+5 more sites) |
| Start date | 2024-12-13 |
| NCT ID | NCT06732141 |
| Official listing | https://clinicaltrials.gov/study/NCT06732141 |